Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of...

por Krüger, Klaus, Burmester, Gerd Rüdiger, Wassenberg, Siegfried, Thomas, Matthias H.
Publicado 2020

Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional...

por Krüger, Klaus, Burmester, Gerd R, Wassenberg, Siegfried, Bohl-Bühler, Martin, Thomas, Matthias H
Publicado 2018

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany

por Krüger, Klaus, Burmester, Gerd R., Wassenberg, Siegfried, Bohl-Bühler, Martin, Thomas, Matthias H.
Publicado 2018